FDA Greenlights First Treatment for Severe Food Allergies

The US Food and Drug Administration (FDA) approved omalizumab, marketed as Xolair, to treat various food allergies in people aged 1 year or older. Omalizumab is a monoclonal antibody that blocks immunoglobulin E, a protein that triggers allergic reactions, including severe ones like anaphylaxis. The FDA first approved the drug in 2003 for treating allergic asthma.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research